Kathryn Penkus Corzo - 31 Oct 2025 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)

Reporting relationship: Director
Issuer ticker: MRKR
Reported as of: 31 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2025, 17:09:13 UTC
Prior SEC filing: 03 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Kathryn Penkus Corzo

Key filing fact

Kathryn Penkus Corzo filed Form 4 for Marker Therapeutics, Inc. (MRKR) on 04 Nov 2025.

Key facts

This page summarizes Kathryn Penkus Corzo's Form 4 filing for Marker Therapeutics, Inc. (MRKR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Nov 2025, 17:09.

Change

Previous filing in this sequence was filed on 03 Nov 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001884123 Primary reporting owner

Corzo Kathryn Penkus

Relationship: Director
Address: MARKER THERAPEUTICS, INC., 2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE, HOUSTON
Signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Kathryn Penkus Corzo
Signature date: 04 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRKR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +147,611
Change %
Price: $0.000000
Shares after: 147,611
Date: 31 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 147,611
Exercise price: $0.9877
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. The shares vest equally over thirty six (36) monthly installments, subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, October 31, 2025.